title: Treatment of stage I breast cancer: the NSABP experience.
abstract: The results of two clinical trials carried out by the National Surgical Adjuvant Breast and Bowel Project are presented. A total of 559 histologically node-negative patients were randomised and assigned treatment in the two protocols. In the oestrogen receptor-negative patients with breast cancer, treatment with methotrexate and 5-fluorouracil produced a 31% reduction in treatment failure at 4 years when compared to no systemic treatment. In the oestrogen receptor-positive patients, treatment with tamoxifen produced a 26% reduction in treatment failure at 4 years in comparison to placebo treatment. In both protocols, this benefit was observed both in patients aged under and over 50 years.
authors.affiliation: National Surgical Adjuvant Project for Breast and Bowel Cancers (NSABP), University of Pittsburgh, Pa.
authors.forename: C
authors.initials: C
authors.lastname: Redmond
authors.forename: C K
authors.initials: CK
authors.lastname: Fisher
authors.forename: B
authors.initials: B
authors.lastname: Costantino
authors.forename: J
authors.initials: J
authors.lastname: Wickerham
authors.forename: D L
authors.initials: DL
authors.lastname: Wolmark
authors.forename: N
authors.initials: N
authors.lastname: Fisher
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000502:physiology; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D011960:Receptors, Estrogen; D013629:Tamoxifen; D005472:Fluorouracil; D008727:Methotrexate